Now there is a general agreement that activating mutation of EGFR is a strong predictor of efficacy for TKI in advanced NSCLC, while the application of adjuvant TKI in NSCLC patients after radical operation is still under research. Here, EGFR is linked to non-small cell lung carcinoma.